FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antibody against human CD147 or its antigen-binding fragment, which activates signal transduction by means of CD147 (options), an antitumor composition containing the above-mentioned antibody, where tumor is tumor expressing CD147, a method for the treatment of tumor expressing CD147, and the use of an antibody, or its antigen-binding fragment, or a composition for the treatment of tumor, where tumor is tumor expressing CD147.
EFFECT: invention expands the arsenal of remedies against CD147.
34 cl, 50 dwg, 8 tbl, 26 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
Authors
Dates
2022-12-06—Published
2018-07-26—Filed